Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | iStopMM: benefits and harms of screening for myeloma precursor disease

Sigrun Thorsteinsdottir • 12 Dec 2021
ASH 2021
Multiple Myeloma Rare Diseases Smoldering Myeloma
iStopMM

Sigrun Thorsteinsdottir, MD, National University Hospital of Iceland, Reykjavik, Iceland, discusses the potential impact of the ongoing iStopMM study assessing the benefits and harms of screening the general population for smoldering multiple myeloma (NCT03327597). Dr Thorsteinsdottir explains that if the study finds that screening positively impacts overall survival (OS) and quality of life (QoL), it could be introduced into clinical practice. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Sigrun Thorsteinsdottir

2:10
Results of iStopMM: prevalence of smoldering myeloma in the general population
Sigrun Thorsteinsdottir • 12 Dec 2021
0:42
iStopMM: a new, large & unbiased MGUS patient population
Sigrun Thorsteinsdottir • 12 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals